KetosisNCT04309214
Market Research - Acceptability Study for New MCT Fat Products
A study testing MCT fats in people with Ketosis and Epilepsy, run by Dr. Schär AG / SPA at 1 site in United Kingdom.
Trial summary
This is a market research, observational study to evaluate the tolerability and acceptability of MCT supplements for young children, young people and adults with intractable epilepsy, GLUT-1 or PDHD from 3 years to adulthood. Read more about this study
- Who is it for?
- Ages 3 to 20 years
- Conditions the study is for
- Ketosis, Epilepsy, Fatty Acid Oxidation Disorder
- What is being tested?
- MCT fats
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 26 Nov 2018to 21 Jan 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 20 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Diagnosis of epilepsy requiring a ketogenic or a specialist diet as part of their treatment.
- Subjects new to taking or who are already taking an MCT product and are willing to try each of the 3 study products for 7 days each. 21 days taking product with 2 days between each new product trialled.
- Those patients who have been taking MCT in their diet should do so for a minimum of 4 weeks before commencement of the study.
- Patients aged 3 years of age to adulthood.
- Written informed consent obtained from patient or parental caregiver.
Who cannot join
- Presence of serious concurrent illness
- Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements
- Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
- Any patients having taken antibiotics over the previous 2 weeks leading up to the study
- Patients already on and MCT product who have been taking it in their diet for less than 4 weeks
- Patients less than 3 years of age
- Patients over 20 years.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Royal Aberdeen Children's Hospital
Aberdeen, Grampian, AB25 2ZG
About this study
Official title: Market Research - Acceptability Study for a Range of New MCT Based Products (Dr Schär - Kanso) Kanso DeliMCT 53% (Cream) Kanso DeliMCT 28% (Tomato or Mushroom) Kanso DeliMCT 21% (Cacaobar)
This is a market research, observational study to evaluate the tolerability and acceptability of MCT supplements for young children, young people and adults with intractable epilepsy, GLUT-1 or PDHD from 3 years to adulthood.
- Conditions
- Ketosis, Epilepsy, Fatty Acid Oxidation Disorder, Malabsorption, Ketogenic Diet, Medium Chain Triglycerides
- Being tested
- MCT fats
- Medical subject headings
- Ketosis, Epilepsy, Malabsorption Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MCT fatsDietary supplement
Also called medium chain triglycerides
Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
| Study group | Role | What they receive |
|---|---|---|
| MCT fats | Experimental | MCT fats to be consumed, one portion per day to ensure tolerance and compliance to the product whilst support the dietary management for a range if disease states namely, the ketogenic diet, fatty acid oxidation disorders and malabsorption. Receives: Dietary Supplement: MCT fats |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gastrointestinal tolerance
Questionnaire detailing any GI symptoms, severity and change from usual The collection of daily data about the gastrointestinal tolerance of the product
Measured: 7 days for each product, maximum 25 days
Product compliance
Daily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount.
Measured: 7 days for each product, maximum 25 days
Product palatability
Questionnaire data captured to evaluate taste
Measured: 7 days for each product, maximum 25 days
Product acceptability
Brief tick-box questionnaire on overall liking and acceptability of product
Measured: 7 days for each product, maximum 25 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2020
- Study start26 Nov 2018
- Primary completion21 Jan 2019
- Study completion21 Jan 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for KetosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr. Schär AG / SPA
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04309214
- Sponsor's protocol ID
- Kanso 2
- Status last verified
- Mar 2020
- First submitted
- 9 Mar 2020
- Last updated
- 16 Mar 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This study will be used for the registration and reimbursement for the products used as foods for special medical purposes.
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Market Research - Acceptability Study for a Range of New MCT Based Products (Dr Schär - Kanso) Kanso DeliMCT 53% (Cream) Kanso DeliMCT 28% (Tomato or Mushroom) Kanso DeliMCT 21% (Cacaobar)
- ClinicalTrials.gov ID
- NCT04309214
- Acronym / sponsor ID
- Kanso 2
- Conditions
- Ketosis, Epilepsy, Fatty Acid Oxidation Disorder, Malabsorption, Ketogenic Diet, Medium Chain Triglycerides
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Dr. Schär AG / SPAIndustry (pharma, biotech, devices)
- Study start
- 26 Nov 2018 (actual)
- Primary completion
- 21 Jan 2019 (actual)
- Study completion
- 21 Jan 2019 (actual)
- First posted
- 16 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a market research, observational study to evaluate the tolerability and acceptability of MCT supplements for young children, young people and adults with intractable epilepsy, GLUT-1 or PDHD from 3 years to adulthood.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MCT fats | Experimental | Dietary Supplement: MCT fatsMCT fats to be consumed, one portion per day to ensure tolerance and compliance to the product whilst support the dietary management for a range if disease states namely, the ketogenic diet, fatty acid oxidation disorders and malabsorption. |
Who may qualify
- Ages
- 3 to 20 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Diagnosis of epilepsy requiring a ketogenic or a specialist diet as part of their treatment.
- Subjects new to taking or who are already taking an MCT product and are willing to try each of the 3 study products for 7 days each. 21 days taking product with 2 days between each new product trialled.
- Those patients who have been taking MCT in their diet should do so for a minimum of 4 weeks before commencement of the study.
- Patients aged 3 years of age to adulthood.
- Written informed consent obtained from patient or parental caregiver.
Key exclusion criteria (7 listed)
- Presence of serious concurrent illness
- Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements
- Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
- Any patients having taken antibiotics over the previous 2 weeks leading up to the study
- Patients already on and MCT product who have been taking it in their diet for less than 4 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MCT fatsAlso: medium chain triglyceridesSubjects will be asked to take 3 new MCT products for 7 days each over a 25 day period | Dietary supplement | MCT fats |
Primary outcome
Gastrointestinal tolerance
Time frame: 7 days for each product, maximum 25 days
Questionnaire detailing any GI symptoms, severity and change from usual The collection of daily data about the gastrointestinal tolerance of the product
Product compliance
Time frame: 7 days for each product, maximum 25 days
Daily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount.
Product palatability
Time frame: 7 days for each product, maximum 25 days
Questionnaire data captured to evaluate taste
Product acceptability
Time frame: 7 days for each product, maximum 25 days
Brief tick-box questionnaire on overall liking and acceptability of product
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2020.
- Individual participant dataSharing planned: No. This study will be used for the registration and reimbursement for the products used as foods for special medical purposes.
Related trials for Ketosis
Recruiting
Variations in Ketone Metabolism
Ketosis
Not yet recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
Healthy Volunteers and Diabetes Participants
Recruiting
LIfestyle MEtabotype Study B (LIME-B)
Nutritional and Metabolic Diseases, Prediabetes
RecruitingObservational study
The ATP Project (Antipsychotic-TEP-Psychosis)
First Episose Psychosis, Metabolic Disease
RecruitingObservational study
Health, Imaging, and Cognition Across the Menopausal Transition
Menopause
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MCT fats in people with Ketosis and Epilepsy, run by Dr. Schär AG / SPA at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gastrointestinal tolerance (time frame: 7 days for each product, maximum 25 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2020.